Our data suggest that rabeprazole and pantoprazole can inhibit FOXM1 and provide a targeted therapeutic option for breast cancer patients and other cancers with aberrant FOXM1 expression, laying the foundation for developing FOXM1-targeted personalized treatment approaches in future. Here, FOXM1 is linked to breast carcinoma.